Scholarlink

Purpose <p>To assess the treatment efficacy, long-term outcomes and ocular toxicity of ultra-low-dose radiotherapy (4&#xa0;Gy) in managing conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.</p> Methods <p>This study retrospectively analyzed 15 patients with conjunctival MALT lymphoma between 2020 and 2022, who received 4&#xa0;Gy radiotherapy (RT) delivered in consecutive 2-Gy fractions. The long-term outcomes included response rate, response time, recurrences or progression, and RT-related toxic effects.</p> Results <p>fifteen patients (eight males, seven females) all had histopathologically confirmed MALT lymphoma, which localized within unilateral or bilateral conjunctiva. At a median follow-up of 30&#xa0;months (range, 9–48), complete response (CR) was observed in 89% of cases (n = 13) and partial response (PR) in 11% (n = 2), with a median time to CR of 2&#xa0;months (range 1–12). Neither local nor distant recurrences were observed, and no disease progression occurred. There was no acute toxic effect in patients after RT.&#xa0;Only three patients developed mild dry eyes as a late treatment toxicity.</p> Conclusion <p>Ultra-low-dose RT presented an outstanding therapeutic effect on conjunctival MALT lymphoma with acceptable toxicity. Further studies like randomized controlled clinical trials can provide more evidence for clinical management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The clinical outcomes of ultra-low-dose radiotherapy for primary conjunctival mucosa-associated lymphoid tissue lymphoma

  • 期刊论文

  • 发表日期：

    2025年6月27日

查看全文
  • Xinxin Chen,
  • Mengting Wei,
  • Pei Mou,
  • Zhe Zhou,
  • Ruili Wei

摘要

Purpose

To assess the treatment efficacy, long-term outcomes and ocular toxicity of ultra-low-dose radiotherapy (4 Gy) in managing conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.

Methods

This study retrospectively analyzed 15 patients with conjunctival MALT lymphoma between 2020 and 2022, who received 4 Gy radiotherapy (RT) delivered in consecutive 2-Gy fractions. The long-term outcomes included response rate, response time, recurrences or progression, and RT-related toxic effects.

Results

fifteen patients (eight males, seven females) all had histopathologically confirmed MALT lymphoma, which localized within unilateral or bilateral conjunctiva. At a median follow-up of 30 months (range, 9–48), complete response (CR) was observed in 89% of cases (n = 13) and partial response (PR) in 11% (n = 2), with a median time to CR of 2 months (range 1–12). Neither local nor distant recurrences were observed, and no disease progression occurred. There was no acute toxic effect in patients after RT. Only three patients developed mild dry eyes as a late treatment toxicity.

Conclusion

Ultra-low-dose RT presented an outstanding therapeutic effect on conjunctival MALT lymphoma with acceptable toxicity. Further studies like randomized controlled clinical trials can provide more evidence for clinical management.